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ABSTRACT 
 
Introduction:  As patients with pancreas and periampullary cancer (PPC) experience improved 
survival rates and longevity, the focus shifts towards living life while surviving cancer.  Fatigue 
is the most commonly reported symptom in all cancer patients. Exercise has been found to 
effectively decrease fatigue levels and improve physical functioning in cancer patients.  
Methods: One hundred and two patients with resected PPC consented to participate in this study 
and were randomized to either an Intervention Group (IG) or a Usual Care Group (UCG).  
Subjects completed visual analog scales, the FACIT-Fatigue Scale (FFS) and the Short Form -
36v2® after surgery and again 3 to 6 months after hospital discharge.   
Results: Patients in the IG and UCG were comparable with regard to demographics, co-
morbidities, cancer type and staging, type of resection, pre-op fatigue and pain levels, adjuvant 
therapy and baseline walking distance.  Patients in the IG had significantly improved scores on 
the FFS at study completion, improved fatigue and pain scores, as well as overall physical 
functioning and mental health composite scores.  At study completion, participants in the IG 
were walking twice as far and were significantly more likely to have continued walking or 
another form of exercise as compared to the UCG.  Using hierarchical cluster analysis three 
mutually exclusive symptom groupings were identified in the cohort.  Kaplan-Meier survival 
analysis did not indicate an overall survival benefit for the IG.  
Conclusion:  This is the first prospective, randomized and controlled trial to report that 
participation in a home walking program confers a significant benefit in resected PPC patients 
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with regard to fatigue levels, physical functioning and HRQOL.  (ClinicalTrials.gov number, 
NCT00902759). 
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INTRODUCTION 
 
Approximately 50,000 new cases of pancreas and peri-ampullary (PPC) adenocarcinoma 
occur annually in the United States (1).  Surgical resection offers the possibility of long-term 
survival with 5-year survival rates varying from 10 to 50%, depending upon such factors as 
pathologic staging, patient performance status and individual institutional volumes (2 - 8).  As 
patients with PPC experience improved survival rates and longevity, the focus shifts towards 
living life while surviving cancer, managing adverse symptoms, and improving physical 
functioning and quality of life (QOL).   
Fatigue and pain are the most commonly reported symptoms by all cancer patients 
including those undergoing chemotherapy (CT) and radiation therapy (RT).  Fatigue is the most 
universally reported symptom and is considered by many patients as more distressing than pain 
(9, 10).  For example, when 600 postings from pancreas cancer patients and their families in a 
monitored Internet pancreas cancer Frequently Asked Questions chat room were analyzed― 
pain, fatigue, and anorexia were the most frequently reported symptoms by post-operative 
patients as well as those who did not have surgery (11).  Other investigations have reported 
fatigue, pain, weight loss, nausea, anorexia, constipation, diarrhea, insomnia, depression, and 
anxiety as the most prevalent symptoms reported by PPC patients at all stages of disease (6,12-
15). 
Fatigue is defined in this study as cancer- related fatigue (CRF), described by the 
National Comprehensive Cancer Network (NCCN) as “a distressing persistent, subjective sense 
of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer 
treatment that is not proportional to recent activity and interferes with usual functioning”, and is 
also referred to as rest-resistant fatigue (16,17).  CRF typically leads to decreased activity levels, 
contributes to a reduction in one’s overall QOL and is often accompanied by anxiety and 
depression.  CRF is known to be a complex process that is influenced by muscle catabolism and 
 5 
protein loss, weight loss, a decline in neuromuscular efficiency, de-conditioning, cancer 
treatment factors, decreased sleep, insomnia and anemia (17,18).  
Exercise, defined as planned, structured and repetitive body movement, has been found to 
effectively decrease fatigue levels and improve functional capacity in patients with breast and 
prostate cancer (19,20).  Exercise increases muscle mass, promotes flexibility and elevates mood, 
all of which improve one’s ability to cope following cancer surgery and during adjuvant therapy.  
Cancer patients who exercise on a regular basis may reduce their fatigue level by one-half.  
Although it may seem paradoxical, fatigue that results from exercise helps reduce CRF by 
improving the quality and perhaps the quantity of restful sleep.  
A 2011 systematic review by Wanchai et al reviewed 28 of the 89 published studies on 
the effect of non-pharmacologic supportive strategies on CRF in breast cancer patients (21).  The 
results showed that home-based exercise, supervised exercise, education, sleep therapy, and 
complementary therapy were effective strategies to improve QOL and reduce CRF among breast 
cancer survivors.  The majority of the published studies on fatigue and quality of life have been 
conducted in patients with breast cancer, followed by stem cell transplant recipients and lastly 
prostate cancer survivors.  By contrast, this is the first report of a randomized controlled trial that 
prospectively evaluated the effects of a home-based walking program in post-resection PPC 
patients on the primary outcomes of CRF, physical function and QOL.  
 A secondary aim of this trial was to explore the occurrence of persistent self-reported 
symptoms in individuals with PPC following surgical resection.  There is a growing body of 
evidence that individuals affected by cancer often do not present with one isolated symptom, but 
rather with multiple, concurrent symptoms or a symptom cluster (the presence of two or more 
symptoms occurring simultaneously, which may or may not share the same etiology) (22-24).  
Several studies have examined the occurrence of symptoms in patients following resection of the 
pancreas and have found that the most common issues are: foul bowel movements, thirst, 
 6 
frequent urination, poor blood glucose control, heartburn, nausea and vomiting, weight loss, 
abdominal pain, fatigue, and muscle weakness (6,15,25-27).  This study was conceptualized 
using the Levine Conservation of Energy Theory as the theoretical background (28).  In this 
model, fatigue represents ongoing adaptation to the illness state and can be a measurable 
outcome.   
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METHODS 
Trial design:  This investigator-initiated study used a two group, prospective, randomized 
controlled design which consisted of a walking intervention group and a comparison usual care 
control group.  The study was approved by the Clinical Cancer Research Review Committee of 
the Jefferson Kimmel Cancer Center and by the Thomas Jefferson University Institutional 
Review Board prior to enrollment of patients and is registered with ClinicalTrials.gov 
(NCT00902759).  
 A convenience sample of men and women (n = 102) ages 18 years or older with resected 
PPC at the Thomas Jefferson University Hospital Department of Surgery consented to participate 
in this randomized controlled trial. Eligible patients, post-resection of PPC (adenocarcinoma 
only) via pancreatectomy, were referred to the principal investigator (TPY) by three 
pancreatobiliary surgeons (EPK, HL, CJY).  Patients were not eligible if Stage IV metastatic 
disease was found at the time of surgery, if the final pathology revealed other than 
adenocarcinoma, or if co-morbidities such as severe arthritis, dizziness or inability to walk 
prevented the patient from actively participating in a walking program.  Identified patients 
meeting the eligibility criteria were approached while hospitalized following resection or at their 
first post-operative office visit.  After obtaining informed consent, subjects were randomized 
without stratification using a computer-generated randomization schedule and the sealed 
envelope technique to either an Intervention Group (IG) or a Usual Care Group (UCG) in a 1:1 
ratio (See Figure 1).  All subjects had either resection alone or resection plus adjuvant CT and/or 
RT between April 2009 and January 2011.  The study was closed to active follow-up on May 26, 
2011, however the survival data were updated through September 6, 2011.  
Outcome Measures:  The primary study endpoints were to determine the effects of a walking 
program on cancer-related fatigue, physical functioning and QOL after three to six months of 
study participation using reliable and validated measurement tools. Secondary endpoints were 
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overall survival and an exploration of the symptom burden and clustering in this patient 
population. 
Sample Size Calculation:  A sample size of 100 (50 in each group) was deemed necessary based 
on the assumption of approximately a 40% improvement in fatigue, physical functioning, and 
QOL in the UCG versus an anticipated 70% improvement in the IG, based on previous studies 
(19).  Using the sample size table by Simon (29) for a one-tailed test, small to moderate effect 
size due to the exercise intervention, power (1- β) of 0.80 and a level of significance (α) of 0.05, 
it was determined that a minimum of 80 subjects would be needed to detect a difference if one 
existed between the groups.  With 80 patients as a minimum target, additional patients were 
recruited, anticipating some degree of study dropout, problems with the exercise program and 
some patient loss to follow-up.   
Methodology:  Following an initial meeting in which the study protocol and procedures were 
reviewed with all investigators, regular meetings were held with the primary data collectors.  A 
script was developed for the monthly follow-up telephone calls in order to standardize the 
questions asked.  Two investigators (TPY and SAB) conducted the majority of the follow-up 
phone calls.   
 Study screening procedures included a baseline assessment on all subjects either in the 
hospital or in the office, consisting of a targeted physical examination and an observed walk 
using a pre-determined and pre-measured route on the hospital floor or in the outpatient clinic.  
The PI or a co-investigator accompanied the patient during the baseline walk and recorded the 
distance walked (in feet) and/or the amount of time walked.  Emergency equipment and a chair 
were available should they be needed during the walk.  Fatigue and Pain Visual Analog Scales 
(FVAS and PVAS), the FACIT-Fatigue Scale (FFS) questionnaire and the Medical Outcomes 
Study Short Form-36 (SF-36v2®) questionnaire were completed by patients at study entry, but 
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prior to randomization.  The same assessment tools were completed a minimum of 3 months 
after hospital discharge or at the completion of adjuvant therapy (See Figure 2).   
Subjects randomized to the IG were given a graduated walking prescription for a home 
walking program based on Every Step Counts-A Walking Exercise Program for Persons Living 
with Cancer, published by Mock in 1997 (30).  Permission to reproduce this booklet and to use 
the program was granted by the Johns Hopkins University School of Nursing (personal 
communiqué, 2007).  The graduated walking prescription includes three phases and was 
individualized for each patient based on their baseline walk and general physical condition (See 
Figure 3).  Participants were instructed to walk at home, in their neighborhood (if safe), at an 
exercise gym or in a shopping mall for as far as possible on a level surface, wearing appropriate 
footwear.  They were instructed to stop or slow down if they experienced physical symptoms 
such as uncomfortable shortness of breath, chest pain, or bodily pain.  The goal was to eventually 
walk for 90 - 150 minutes per week in three to five sessions.  In order to reduce the perceived 
burden of the program, participants were not asked to routinely take their pulse or to record their 
perceived exertion, but the exercise booklet describes how to do this if they chose to.   
 Patients in the IG were also asked to keep a weekly diary-type log of the number of 
minutes or the approximate distance walked at each session and to record in the log any adverse 
symptoms experienced during the week.  Self-addressed, stamped envelopes were provided and 
additional log sheets were mailed to the participants as needed.  Patients in the IG also received a 
monthly follow-up telephone call from either the PI or a co-investigator for two purposes:  to 
provide a reminder to mail in the log sheets and to assess their current status using a pre-
determined set of standardized questions.  These standardized questions included their current 
medical condition, adherence with the walking program, the amount and type of exercise 
performed, their current FVAS and PVAS rating, chemotherapy or radiation therapy being 
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received, and the presence or absence of the following 10 symptoms: fatigue, pain, shortness of 
breath, weight loss, anorexia, diarrhea, constipation, weakness, insomnia, and depression. 
 This 10 symptom profile survey was based on a literature review of the most commonly 
reported symptoms in patients with PPC (6, 11, 12-15, 24-27), and was administered to the IG 
during monthly follow-up phone calls and upon final follow-up.  The UCG received the follow-
up 10 symptom profile survey only upon final follow-up.  To ensure the consistency of our 
follow-up symptom survey findings, subject responses were crossed-checked with FACIT-
fatigue scores, pain and fatigue visual analog scores, and the SF-36 Health Survey responses.  
During the monthly follow-up calls, if an IG patient was feeling particularly low due to the 
administration of chemotherapy or radiation therapy that day, we called them back the following 
week, (recognizing that symptoms are heavily influenced by the effects of treatment).  We were 
also consistent about the time of day that we called and found that the afternoon between 4 - 5 
PM was a reliable time to reach patients and a time when they were willing to talk with us.  This 
allowed patients to reflect on their symptoms over the course of the day increasing the likelihood 
that their responses reflected the average daily symptom ratings.   
 The patients in the UCG did not receive a monthly phone call.  They received a study 
follow-up telephone call from the PI or co-investigator, beginning 3 months following entry into 
the study.  In some instances it took several months to reach patients in the UCG group for 
follow-up.  At the time of follow-up, they were asked to complete the 10 symptom profile 
survey, as well as the FVAS, PVAS, FFS, and the SF-36v2® assessment tools.  The FFS and SF-
36v2® questionnaires were completed on the telephone with the investigator or if so requested, 
the forms were mailed to the subject for completion. 
TOOLS UTILIZED: 
Exercise Program:  The Every Step Counts graduated walking program was implemented in 
this study with minor modifications for resected PPC patients (30) (See Figure 3).  The 
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modifications included: reducing the length of the program from six months to three months, and 
recommending a more gradual increase in brisk walking time to 10 minutes in the first month, 20 
minutes in the second month and 25-30 minutes in the third month.  An individual “Exercise 
Prescription” was given to the IG patients at the time of entry into the study, as well as a copy of 
the Every Step Counts booklet. 
Fatigue and Pain Visual Analog Scales (FVAS and PVAS):  Visual numeric rating scales 
(visual analog scales - VAS) for pain and fatigue were used in the study and are valuable for 
obtaining ordinal measures of pain and fatigue and to serve as exploratory measurement tools.  
Numeric scales can be corroborated with targeted tools that address more than just severity of the 
symptom (31).  Fatigue and pain VAS were obtained at baseline and at each follow-up phone 
call with the IG, and at the end of the study in both the UCG and the IG. 
FACIT-Fatigue Scale (FFS): The FFS is a standardized 13-item fatigue subscale of the FACT-
F developed in 1997 from 32 items submitted by five medical experts and 221 items from 14 
cancer patients (32).  It has high test-retest reliability (r = 0. 87) and internal consistency (α = 
0.95 and 0.93), supporting its ability to be used as an independent, one-dimensional measure of 
fatigue.  One of the advantages of the FFS is that it asks patients to consider their answers in the 
context of the last 7 days.  This approach is considered to be representative of  average feelings 
and is less influenced by the high and low ends of the fatigue spectrum or by treatment effects.  
The FFS was administered at baseline, at each follow-up phone call with the IG, and at the end 
of the study in the both UCG and the IG.  
ECOG Performance Status Rating Scale: The ECOG performance status rating scale is a six 
level (0, fully functional – 5, deceased) assessment tool that provides a measure of physical 
function by assessing the degree to which cancer patients are able to participate in the activities 
of daily living, as well as their need for rest (33).  It is a global index which has been widely used 
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in clinical trials to assess the functional capability of cancer patients.  We used the ECOG level 
for a baseline and follow-up measure of performance ability in both the IG and UCG. 
Short Form-36v2® Health Survey (SF-36v2®):  The SF-36v2® is a comprehensive, valid and 
reliable multipurpose general health survey (34, 35).  It is not targeted to a specific disease, age 
group or treatment group, but rather assesses health concepts that are universally valued (35).  It 
consists of 36 questions addressed through eight domains (cognitive functioning, sleep, health 
distress, social support, family and marital functioning, sexual functioning, physical symptoms 
and psychological symptoms) and 1 transitional question.  Two psychometrically based 
composite scores, the Physical Component Summary (PCS) and the Mental Component 
Summary (MCS) are generated using the QualityMetric Health Outcomes TM scoring Software 
(Version 3.0.21129. Copyright 2004-2009).  These two composite scores are considered a valid 
representation of health-related quality of life (HRQOL) and indicate the extent to which 
physical or mental problems interfere with the eight domains of life (36).  The SF-36v2® is 
based on norms developed from the 1998 National Survey of Functional Health Status, and it 
measures a 4 week recall period. Of the 36 questions on the questionnaire, 14 questions address 
physical functioning, 2 questions assess bodily pain, 5 questions reflect general health, 4 
questions reflect one’s vitality, 2 questions address social functioning, 11 questions concern 
mental health, and one question assesses health transition and estimates the average change in 
health status in the year prior to administration.  However the health transition question is not 
used in scoring the scales or in the summary measures.  The SF-36v2® has been studied in 
multiple investigations and reliability coefficients range from 0.8 to 0.93 (37).  The two 
composite measures, PCS and MCS, are reliable composite measures of the domains included in 
their compilation and together can be used to indicate one’s HRQOL.  The percent of the sample 
at-risk for depression is also calculated based on the normogram.  Lower scores on the PCS 
reflect limitations in self-care, physical function and social and role activities, frequent tiredness, 
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and rating of one’s health as poor. Lower scores on the MCS indicate frequent psychological 
distress and social and role disability due to emotional issues.  Obtaining a high PCS or MCS 
requires more than just freedom from physical limitations and social and role disability; it 
requires that the respondent rated their health as “excellent”.  Rating one’s overall health as very 
good, good, fair or poor affects both of these composite measures.  Likewise rating one’s health 
as “excellent” is not sufficient for a very high score.  The PCS and MCS weight the personal and 
social implications considerably. 
Monthly Exercise Diary:  Patients in the IG were asked to use a self-reported diary-log to 
record the length of time and/or the approximate distance that they walked or exercised each 
week.  They were also asked to record any adverse and bothersome symptoms that they 
experienced either during walking or at other times.  The logs were to be mailed to the PI on a 
monthly basis.  
Statistical Analysis:  All data were initially entered into an Excel database and later transferred 
to Stata-Version 8 and SAS Version 9.2 statistical packages for data analyses.  Baseline 
descriptive statistics were computed for the IG and UCG.  χ² testing and linear and logistic 
regression models were used for comparing continuous and categorical variables.  T-tests and 
paired t-tests were used to compare the continuous variables. Survival analysis was conducted 
using the Kaplan-Meier method and the Cox proportional hazards model.  Symptom analysis was 
performed using hierarchical cluster analysis.  Distances between subjects were calculated using 
the Gower dissimilarity measure, and clustering was performed using the Centroid method.  
Statistical significance was set at p ≤ 0.05.  Data were analyzed according to the intention to treat 
principle.   
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RESULTS 
 During the study, 165 patients were potentially eligible for participation, based upon their 
final pathology and operative procedure performed (Figure 1).  Forty seven (47) were not 
approached due to complications limiting recovery, social issues, administrative lapses or clear 
inability to exercise.  The remaining one hundred eighteen (118) patients were approached to 
participate in the study.  Eight (8) patients declined participation because they felt too ill, were 
not interested or felt that they were not fluent enough in English to participate.  Thus, 110 
patients were enrolled in the study; 102 had sufficient data to be included in the analysis.  
Twenty-three subjects were censored during the study period; 15 died during the study period, 3 
withdrew from the study, and 5 were lost to follow-up.  At the last survival follow-up (9/6/11), 
the median follow up was 19 months, and there were 27 confirmed deaths in the total cohort, 12 
deaths in the IG and 15 deaths in the UCG.  Seventy-nine (79) of the 102 patients enrolled 
completed the study. 
Demographic and Clinical Characteristics (Table 1): 
The allocation yielded two groups with comparable demographic and clinical 
characteristics, indicating effective randomization.  The mean age of patients in the IG was 66 
years and 67 years in the UCG.  Half of the patients were men, most were white, and over 90% 
of the patients had a pathologic diagnosis of primary pancreatic ductal adenocarcinoma.  Most 
patients had either Stage 2a or 2b tumors (73% and 72% in the IG and UCG, respectively) and 
over 90% in each group had a pylorus-preserving pancreaticoduodenectomy.  Co-morbidities in 
the groups were similar with hypertension, diabetes, coronary artery disease and a previous 
history of cancer being the most commonly identified conditions.  Over half of each group self-
identified as either current or previous cigarette smokers.  There were no significant differences 
between groups with regard to pre-operative serum values of albumin, glucose, total bilirubin, 
hemoglobin and the tumor markers CEA and CA 19-9.  The only parameter that was 
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significantly different was study entry body mass index (BMI).  The BMI in the IG was 28, as 
compared to 26 in the UCG (p = 0.02).  Data were available on adjuvant chemotherapy for 53 IG 
patients and 46 UCG patients, with 5-flourouracil and gemcitabine being the chemotherapeutic 
agents received most often.  During the study period, there 7 deaths in the IG compared to 8 
deaths in the UCG.  As concerns follow-up, 74% of the IG and 71% of the UCG completed the 
minimum 3 month follow-up.  A number of patients were followed for up to a year or more, so 
as to obtain as long as possible follow-up. 
Walking Program (Table 2):  
On the initial baseline walk, the UCG on average walked further than the IG (1404 feet 
versus 913 feet, p = N.S.).  The mean distance walked at the time of the first month of follow-up 
by the IG was 2.5 miles. This distance decreased to 1.1 miles at the month 2 interval, which often 
corresponded to the timing of administration of adjuvant therapy.  The distance walked increased 
to 2 miles at the final 3 month walk for the IG.  At the end of the study period, the IG was 
walking twice as far as the UCG (2 miles versus 1 mile, p =0.1, 3- 5 times per week) and the IG 
were significantly more likely (80% vs. 58%) to still be walking or engaged in another form of 
exercise (p = 0.04).   
Fatigue (Table 3): 
 Fatigue scores were assessed at baseline and at a mean follow-up of 3 to 6 months using 
the Fatigue VAS and the FFS.  At entry into the study, 85% of all participants reported moderate 
to severe fatigue (FVAS greater than 5).  Baseline FFS scores (range 0-52) were not significantly 
different between the groups with a mean score of 27 in the IG and 30 in the UCG.  Comparing 
baseline and end-of-study scores between groups, only patients in the IG had significantly 
improved fatigue scores by both fatigue measures at the end of the study, as compared to their 
own baseline (p = 0.05).  Higher FFS scores tended to correlate with lower stage of disease.  
Those reporting lower fatigue scores also had the lowest pain scores.  
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Pain (Table 3):   
 Patients in both groups reported pain in the mild range (PVAS = 2.9) at entry into the 
study, which significantly improved in both groups (to 1.6 in the IG and to 1.8 in the UCG) by 
the end of the study (both p = 0.05).  
ECOG Stage (Table 3):   
 At entry to the study, 95% of the IG were ECOG levels 1 and 2, while in the UCG, 87% 
were ECOG levels 1 and 2, and 6% were ECOG 0.  The baseline ECOG scores for both groups 
indicate that most participants were somewhat restricted in performing physically strenuous 
activity but were ambulatory and able to perform some light work.  Neither the pre-ECOG scores 
nor the post-ECOG scores differed significantly between the groups, but there was a trend 
towards less self-care and less ability to carry out any work activities in the UCG at the end of 
study, and their ECOG score rose at study end (1.5 to 1.8), while the ECOG score in the IG fell 
(1.6 to 1.5).    
Short Form-36v2® (Tables 4 and 5):   
The overall quality of the SF-36v2® questionnaire data was acceptable for both the IG 
and UCG, with the data quality indicators for completeness of data, responses in range, 
consistency, internal consistency, discriminate validity, and reliability ranging from 87% to 
100% in all 8 domains (data indicators are most desirable when greater than 90%). On baseline 
assessment, the UCG showed slight response inconsistencies with data indicators at 86 %, 87%, 
and 88% in 3 areas. The data indicators for the end-of-study questionnaires were in the 90% or 
better category in all but one area, which was 89%.  The SF-36v2® scoring algorithms require a 
response for at least half of the items in each of the domains for accurate interpretation (37).   
As shown in Table 4, at study entry the IG had significantly poorer physical functioning 
(p = 0.02) as compared to the UCG.  The remaining seven of eight domains were comparable 
between the two groups.  The scores of both the IG and the UCG improved over the study period 
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in all domains except the General Health domain.  For the IG, the post-intervention scores were 
significantly improved in six domains, while for the UCG, the post-intervention scores were 
significantly improved in only four domains.  For the two composite scores the PCS and the 
MCS both significantly improved in the IG, while only the MCS significantly improved in the 
UCG (all p = 0.05). 
As shown in Table 5, the IG was below the 50th percentile of the U.S. normative data in 
six of the eight pre-intervention domains, while the UCG was below the 50th percentile in five of 
the eight pre-intervention domains.  At the conclusion of the study the scores for both groups 
improved in all domains except the General Health domain.  The IG remained below the 50th 
percentile norm in two areas (physical functioning and physical role) and the UCG remained 
below the 50th percentile norm in one area (physical role).  Overall, we observed a larger 
percentage improvement, compared to U.S. norms in the IG, as compared to the UCG.   
Depression (Table 5):  
 At the beginning of this study, 61% of the UCG answered “yes” when asked if they were 
experiencing depression, as compared to 45% of the IG.  At the end-of-the study, the SF-36v2® 
scoring identified 15% of the IG and 9% of the UCG as at-risk for depression as compared to the 
general U.S. population.  In both the IG and the UCG, those with higher mental health composite 
scores reported less depression, higher physical functioning scores and had lower stage of 
disease at the end of the study.  
Survival (Figures 4a and 4b):  
 Overall survival during the study period for all patients with resected PPC did not differ 
between the IG (range:  72 days -2.3 years) and the UCG (range:  44 days – 2.3 years).  As of 
this report median survival has not been reached in either group (See Figure 4a).  Using Cox 
regression to compare survival only in cases of resected pancreatic adenocarcinoma, we found a 
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hazard ratio of 1.3 (CI 0.7 – 2.5) for the UCG as compared to the IG, indicating a small trend 
towards a survival advantage in the IG (see Figure 4b; p = 0.56).  
Symptom Analysis (Table 6):  
 We examined the cohort’s symptom profile to determine which symptoms occurred at the 
same point in time.  Cluster analysis after the 3 month time point was used to identify the 
presence of symptom clusters.  Overall the cohort reported an average of 4.5 out of ten 
symptoms, with 92% reporting 2 or more symptoms at a mean of 3 months after resection.  The 
five most commonly reported symptoms were fatigue, pain, depression, anxiety and weakness.  
The UCG reported a greater frequency of symptoms compared to the IG patients, but not 
significantly more.  Using hierarchical cluster analysis, three mutually exclusive symptom 
groupings were identified in the cohort.  The first and most prevalent symptom cluster grouping 
(n=61) included fatigue (97%), bodily pain (72%), depression (69%), weakness (67%), and 
anxiety (64%), as well as trouble sleeping (30%) and shortness of breath (20%).  Patients in this 
first cluster have not yet reached median survival (greater than 22 months).  Given the high 
prevalence of fatigue in this first cluster we then re-analyzed this seven-symptom cluster without 
the symptom of fatigue and no sub-grouping was present, suggesting that fatigue is the central 
component of this PPC patient cluster, and that these symptoms may share a common biological 
mechanism.  The second symptom cluster grouping (n=33), represented a group of sicker 
patients and the cluster contained only fatigue (18%) and shortness of breath (6%) as the 
predominant symptoms.  Despite their low symptom reporting, patients in this second grouping 
experienced poorer survival (median survival = 9.3 months) had a more advanced stage of 
cancer, had poorer baseline and final ECOG scores, and fewer received adjuvant therapy.  The 
third and least prevalent symptom cluster grouping (n=8) included fatigue (88%), diarrhea 
(88%), pain (63%) anxiety (38%) and trouble sleeping (13%).  This third group also had poorer 
survival than the first group, with a median survival of only 10.7 months.   
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DISCUSSION 
This is the first study to date to prospectively evaluate the effects of a structured home-
walking program in patients following resection for pancreatic and periampullary 
adenocarcinoma.  Patients were approached after recovery from major pancreatic resection, 
signed appropriate informed consent, completed various validated assessment tools, and were 
randomly allocated to the intervention group (IG) or the usual care group (UCG).  At the 
conclusion of the study the IG and the UCG appeared to be well matched with regard to 
demographics, pathological parameters and baseline clinical characteristics (Table 1).  Of note, 
the IG at the end of the study reported walking over twice as far as the UCG (Table 2; 2 miles for 
the IG vs. 1 mile for the UCG) and were significantly more likely to still be walking at the study 
end (80% versus 58% in the UCG; p = 0.04).  Using the various validated assessment tools 
(FVAS, FFS, PVAS and SF-36) the IG was observed to have improvements in fatigue, pain, and 
physical composite scores that exceeded the improvements observed in the UCG.  Of note, the 
IG received an exercise prescription, a detailed exercise booklet and a monthly phone call.  The 
phone call was a key component of the protocol.  Not only did the phone call serve as a reminder 
to walk or exercise, but it was also an opportunity to learn about their life after PPC resection.  
The phone call provided us an entry into the details and personal response to their adjuvant 
therapy.  The monthly phone call to encourage the IG to walk and exercise, along with the 
monthly log sheets, we believe were critical to the success of the program.  Patients in general 
were very grateful for the follow-up phone call and it provided us with a great deal of 
information on how they were faring in their recovery.  The structured walking program (Figure 
3), reinforced with regularly scheduled telephone follow-up by a knowledgeable advanced 
practice nurse, likely improved adherence with the protocol.  Even for IG patents that did not 
walk or exercise, the phone call was quite important in establishing rapport and getting a glimpse 
of surviving life following resection of PPC.  One practice implication of the current study is that 
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this type of telephone follow-up should be implemented when feasible, as it appeared to be much 
appreciated by the patients and served as a tangible reminder to persist with their exercise 
prescription.  
 We found that the adverse symptoms related to chemotherapy (such as nausea, vomiting, 
and anorexia) peaked one to two days after chemotherapy and dissipated in 1 to 3 days, with a 
return to baseline symptom status thereafter.  Patients in the IG typically had an “exercise break” 
during this period and many returned to walking the following week.  We noted that symptoms 
reported during adjuvant therapy often reflect an increased symptom intensity due to the 
treatment.  Therefore it is important to time the collection of data to minimize capture at these 
peak times (unless the intent of the study is to capture therapy-related side effects).  
Since clinical practice is unlikely to be altered by this one study and replication studies 
are needed to truly affect practice,  a prospective randomized longitudinal study which includes a 
walking component and an objective measure of energy expenditure (such as the use of a 
pedometer, “body bug” or other electronic monitoring device to quantify movement) is needed.  
Support for recommending exercise in cancer survivors is abundant. Schmitz et al conducted a 
systematic review and meta-analysis including data extracted from 22 high-quality studies (38).  
They found qualitative and quantitative evidence of a small to modest effect of physical activity 
on cardiopulmonary fitness during and following cancer treatment, with improvement in 
physiologic outcomes and symptoms. They concluded that physical activity is well-tolerated by 
cancer patients during cancer treatment and afterwards.   
 We found only mild to moderate pain in the patients enrolled in this study.  This may 
have been due to the exclusion of patients with stage 4 disease, routine prescribing of oral pain 
meds, failure to recruit patients with serious perioperative complications, and the inclusion of a 
number of patients who had received a celiac plexus alcohol block at the time of resection (as 
part of an ongoing double blinded RCT at our institution).  One future approach would be to 
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exclude those on pain medications or query the patients more often and keep a diary of pain 
medications taken. We were concerned about “response burden” in this population, and therefore 
we kept the number of measurement tools to a minimum.  
 While this RCT offers evidence of the benefit of a home-walking program in resected 
PPC patients and preliminary evidence of the existence of a fatigue-related symptom cluster 
(fatigue, bodily pain, depression, weakness and anxiety), there are several limitations that must 
be acknowledged.   First, the sample was predominantly Caucasian which limits  applicability to 
other racial and socioeconomic groups.  A second limitation relates to the patients’ pre-diagnosis 
physical activity and our lack of stratification for this variable.  It could be suggested that people 
who were more physically active before their PPC diagnosis may have been more physically 
active after their diagnosis and more willing to participate in the study. While this is a possibility, 
prior exercise experience was not an inclusion criterion of the study, and group designation was 
randomly assigned.  Such randomization should have evenly distributed the pre-diagnosis 
exercisers between the IG and the UCG.  Of note Meyerhardt et al in their investigation of colo-
rectal cancer survivors using data from the Nurses Health Survey, found that pre-diagnosis 
exercise did not affect colo-rectal specific mortality or overall mortality, but post-diagnosis 
exercise did confer reduced colo-rectal mortality (39).  A third limitation (or criticism) of this 
study is that the monthly phone call received by the IG may have been largely responsible for the 
observed improvement in symptomatology, as opposed to the walking program.  This issue 
would be well-addressed in a replication study with an “attention control group” where the UCG 
also receives phone contact, or in a larger prospective longitudinal cohort study utilizing a 
specific MET (metabolic equivalent task) measurement device and more comprehensive 
symptom profile tools.  A fourth limitation addresses the symptom cluster analysis.  In this 
cohort, symptoms may have been caused by the disease, by the treatment (surgery or adjuvant 
therapy), or by the various co-morbid conditions such as arthritides, deconditioning or 
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cardiovascular disease.  As the most predominant fatigue-related cluster (fatigue, bodily pain, 
depression, weakness and anxiety) was identified cross-sectionally at a mean of 3 months 
following surgical resection, it is currently not known if this symptom cluster is present at other 
time points during the resected PPC disease trajectory.  Future research studies should be 
directed to determining the stability of this symptom cluster over time, through longitudinal 
patient investigations.   
In conclusion, this is the first RCT to prospectively evaluate the effects of a structured 
home-walking program in resected PPC patients and to report that participation confers a 
significant benefit with regard to fatigue and pain levels, physical functioning and mental health.  
Although the benefits of exercise programs for cancer patients have been recognized since 1986, 
the optimal regimen is still unclear (17, 40, 41).  There seems to be little harm and much 
potential benefit to patients by recommending that resected PPC patients engage in low-to-
moderate intensity exercise.  Published exercise guidelines for cancer patients emphasize the 
importance of performing an initial clinical assessment and recommend low-to moderate 
exercise intensity (16).  As more patients with pancreas and periampullary cancers experience 
improved survival, it is important to assess the impact that survival has on their lives and to 
strive to return them to their pre-operative performance status.  One tangible result of this study 
is that we now recommend a structured walking prescription to our patients, similar to Figure 3, 
as part of our patients’ discharge instructions.  Physicians, nurses, advanced practice nurses, 
social workers and physical therapists are all instrumental in this process.   
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Table 1:  Demographic, Pathologic and Clinical Characteristics of the Intervention Group 
and the Usual Care Group  
 
Characteristic of Subjects 
(N=102) 
Intervention Group 
(n = 54) 
Usual Care Group 
(n= 48) 
p – 
value 
Age at Time of Surgery (yrs, range) 66 (38 - 87) 67 (48 - 91) 0.7 
Male (n, %) 29 (51%) 28 (49%) 0.6 
Race (n): 
   White 
    Black, Asian, or Hispanic  
 
52 
2 
 
45 
3 
 
0.5 
 
Diagnosis (n,%): 
  Pancreas Ductal Adenocarcinoma 
  Bile Duct Cancer  
  IPMN with Cancer  
  Duodenal Cancer  
 
          50 (93%) 
1 
2 
1 
 
         43 (90%) 
2 
2 
1 
 
0.6 
 
Stage of Cancer (n,%): 
   1 a, b     
   2 a,b                                                                        
   3  
 
6  
             44 (73%) 
4 
 
6 
35 (72%) 
7 
 
0.5 
Type of Surgery (n): 
  Pylorus Preserving Pancreaticoduodenectomy 
  Classic Whipple  
  Distal Pancreatectomy 
 
50 (93%) 
1 
3 
 
44 (92%) 
1 
3 
 
0.7 
Co-morbidities (n,%): 
  Previous cancers 
  Diabetes 
  Hypertension 
  Coronary Artery Disease 
  Cigarette smoking 
 
10 (19%) 
17 (31%) 
35 (65%) 
14 (23%) 
30 (56%) 
 
6 (11%) 
15 (32%) 
25 (52%) 
11 (26%) 
30 (63%) 
 
0.4 
0.9 
0.2 
0.7 
0.5 
Laboratory Values Pre-op (mean):  
  Albumin (mg/dl)  3.6 3.4 0.3 
  Glucose (mg/dl)    142 139 0.8 
  Total bilirubin (mg/dl) 3.4 2.9 0.6 
  Hemoglobin (g/dl) 12 12 0.4 
  CEA  (mcg/L, range) 3.4 (0.5 - 31) 3.6 (0 - 17.5) 0.8 
  CA 19-9 (U/ml, range) 950 (1 - 19,867) 2000 (0.8 - 37,333) 0.6 
BMI baseline (mean, range) 28 (17 - 49)* 26 (19 - 42) 0.02 
Adjuvant Therapy (N,%) (CT, RT or both)  
                                             (None)  
39 (72%) 
15 (28%) 
35 (73%) 
13 (27%) 
0.5 
Most Common Chemotherapy (n,%) 
Gem +/- 5 FU (missing data 3 subjects, 2 had 
other CT) 
34/53 = 64% 24/46 = 52% 0.2 
Deaths: in study period (n, %) 7 (13%) 8 (17%) 0.6 
Deaths: overall (n, %) 12 (22%) 15 (31%) 0.6 
 
* p = 0.02 compared to the UCG 
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Table 2:  Comparison of Walking Program Characteristics:  Intervention Group 
Compared to Usual Care Group 
 
Walking Program Intervention Group  Usual Care Group 
 
p-value 
IG and UCG Baseline Walk  
 (feet, range) (IG = 54, UCG = 48) 
913 (10 - 5280) 
0.17 miles 
1,404 (10 - 7920) 
0.27 miles 
0.1 
IG First Month Walk  
 (feet, range) (n= 38) 
13,412 (420-150,797) 
2.5 miles 
--- --- 
IG Second Month Walk  
 (feet, range) (n = 29) 
5,914 (330 – 73,900) 
1.1 miles 
--- --- 
IG and UCG Final Walk  
(feet, range) (IG =31, UCG =18) 
10,772 (420- 147,840) 
2 miles 
5,219 (1,320-63,360) 
1 mile 
0.1 
Follow-up time (weeks, mean) 12 13 0.9 
Subjects that Completed Study 
 (n = eligible to complete study, i.e.  alive,%) 
41/47 (87%) 35/40 (88%) 0.7 
 Subjects Still Walking at End-of-Study  
 (n, %) 
33/41 = 80%* 18/31 = 58% 0.04 
 
*p-value = 0.04 compared to the UCG 
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Table 3:  Fatigue, Pain, and ECOG Performance Status: Intervention Group Compared to 
Usual  Care Group 
 
Outcome Measures  
 
Intervention  Group 
  ( n= 54)        (n = 47) 
Usual Care Group 
    (n = 48)           (n =40) 
Fatigue Visual Analog Scale (FVAS)  
(mean, range 0-10)  
(Higher Score = More Fatigue) 
Pre 
4.8 
Post 
3.5 * 
Pre 
4.7 
Post 
3.8 
FACIT- Fatigue Scores (FFS)   
(mean, range 0- 52)  
(Higher Score = Less Fatigue) 
27 36* 30 34 
Pain  Visual Analog Scores (PVAS)  
(mean, range 0-10) 
(Higher Score = More Pain) 
2.9 
 
1.6* 2.9 1.8* 
ECOG Stage, (mean, range) 
(Score 0=no limitations – 5=dead) 
1.6 
(1-3) 
1.5 
(0-5) 
1.5 
(0-3) 
1.8 
(0-5) 
 
*p<= 0.05, paired t-tests used in analysis 
 
ECOG = Eastern Cooperative Oncology Group 
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Table 4:  Short Form-36 Health Survey® Pre / Post Intervention Scores 
 
SF-36 Health Survey® Intervention Group Usual Care Group 
8 Domains  Pre 
(n=54) 
Post 
(n=39) 
Pre 
(n=48) 
Post 
(n=35) 
Physical Functioning  34* 43** 39           43** 
Role-Physical 34 41** 38 40 
Bodily Pain 47 53** 42           50** 
General Health 48          46 48 44 
Vitality 44 50** 43           46** 
Social Functioning 37 46** 39           45** 
Role-Emotional 42          47 43 47 
Mental Health 45 51** 44 48 
SF-36v2® Health Survey Scores†** 
 
Physical Composite Scores   (PCS) 
Mental Composite Scores    (MCS) 
 
 
PCS  = 39 
MCS =  45 
 
 
PCS  = 44** 
MCS =  51** 
 
 
PCS  = 40 
MCS =  44 
 
 
PCS  = 43 
    MCS = 48** 
*Pre scores: IG to UCG, p<= 0.05,  
** Paired pre/post t-tests, p<= 0.05. 
SF-36v2® Scoring 20-80: higher scores = better functioning 
 
 
 
 31 
Table 5:  Percent of Study Participants below General Population Norms* on Eight  
               Domains at Baseline and at End of Study 
 
SF-36 Health 
Surveyv2® 
Intervention Group 
(% below Norm) 
Usual Care Group 
(% below Norm) 
Domains Pre 
(n = 54) 
Post 
(n = 39) 
Improved / 
Worsened 
Pre 
(n = 49) 
Post 
(n = 35) 
Improved/ 
Worsened 
Physical Functioning 78% 51% +27% 78% 49% +29% 
Role-Physical 83% 62% +21% 65% 63% +2% 
Bodily Pain 50% 23% +27% 59% 31% +28% 
General Health 35% 44% -9% 31% 43% -12% 
Vitality 57% 31% +26% 39% 37% +2% 
Social Functioning 65% 33% +32% 59% 40% +19% 
Role-Emotional  57% 33% +24% 49% 46% +3% 
Mental Health  44% 28% +16% 51% 31% +20% 
 Physical Function 
Composite Score 
70% 46% +24% 69% 54% +15% 
Mental Health 
Composite Score  
56% 31% +25% 47% 26% +21% 
Depression, At-Risk   24%  15% +9% 18% 9% +9% 
 
* Norms from the 1998 U.S. National Survey of Functional Health Status (Reference #35). 
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Table 6:  End-of-Study Symptom Profile in Intervention Group versus Usual Care Group 
Symptoms  
(n,%) 
Intervention 
Group 
Usual Care 
Group 
p-value 
Fatigue  37/43 (86%) 34/37 (92%) 0.2 
Bodily Pain  18/43 (42%) 21/35 (60%) 0.2 
Weakness 25/43 (58%) 11/37 (30%) 0.9 
Depression  19/43 (44%) 22/36 (61%) 0.3 
Anxiety  16/43 (37%) 26/37 (70%) 0.6 
Diarrhea  12/43 (30%) 11/36 (31%) 0.9 
Constipation  6/43 (14%) 7/37 (19%) 0.6 
Trouble Sleeping  12/40 (30%) 10/35 (29%) 0.9 
Weight Loss  7/43 (16%) 7/37 (19%) 0.6 
Shortness of Breath  9/43 (21%) 5/32 (14%) 0.4 
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FIGURE LEGENDS 
 
Figure 1.  Flow diagram of study participants.  Of the 165 potentially eligible patients, 118 were 
approached for study inclusion, 110 were enrolled, and data were sufficient for 
analysis in 102 patients. 
Figure 2.  Basic design of the study.  Following randomization the patients were allocated to 
either the Intervention Group or the Usual Care Group.  (PPC = pancreas and 
periampullary cancer; FVAS = Fatigue Visual Analog Scale; PVAS = Pain Visual 
Analog Scale; FFS =  FACIT-Fatigue Scale; SF-36 = Short Form – 36 v 2® 
questionnaire) 
Figure 3.   Example of the graduated walking prescription given to patients allocated randomly to 
the Intervention Group. 
Figure 4a.  Kaplan-Meier overall survival curves for the Intervention Group (, n = 54) and the 
Usual Care Group (---, n = 48) for all patients with resected pancreatic and 
periampullary adenocarcinoma.  Median survival has not been reached in either 
group, and the curves are not significantly different.  Time zero is the date of 
resection. 
Figure 4b.  Kaplan-Meier overall survival curves for the Intervention Group (, n = 50) and the 
Usual Care Group (---,  n = 43) for patients with resected pancreatic adenocarcinoma.  
Median survival has not been reached in either group, and the curves are not 
significantly different.  Time zero is the date of resection. 
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      Figure 1: Flow Diagram of Study Participants 
 
 
 
N = 165 
Potentially Eligible Patients 
N = 118 
Patients Approached 
N = 8 
Declined to Enroll: 
- Too sick 
- Poor English skills 
- Not interested 
N = 110 
Patients Enrolled and Randomized 
N = 102 
Sufficient Data to Analyze 
n= 54 
Intervention Group 
(IG) 
n = 48 
Usual Care Group  
(UCG) 
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                  Figure 2:  Study Design 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IDENTIFY ELIGIBLE POST-RESECTION PPC 
PATIENTS 
RANDOMIZE TO INTERVENTION GROUP or 
USUAL CARE GROUP 
USUAL CARE GROUP: 
 -Perform baseline assessment and walk 
- FVAS, PVAS, FFS, SF-36  
- No monthly phone calls 
- Perform usual activity/exercise 
- Repeat questionnaires at 3 - 6 months 
INTERVENTION GROUP: 
-  Perform baseline assessment and walk 
-  FVAS, PVAS,FFS, SF-36 
-  Exercise booklet and prescription before discharge 
-  Monthly exercise logs 
-  Monthly follow-up phone call 
-  Repeat questionnaires at 3 - 6 months 
 36 
 
Figure 3:  Walking Prescription 
 
Name:       Date: 
 
Your Nurse Practitioner:     Phone number: 
 
Month 1:  Phase 1: Warm-up                Walk slowly for:                5 minutes 
 
Phase 2: Brisk Walking        Walk more briskly for:    10 minutes 
 
Phase 3: Cool Down              Walk slowly for:                5 minutes 
Month 2:  Phase 1: Warm-up                Walk slowly for:                5 minutes 
 
Phase 2: Brisk Walking        Walk more briskly for:    20 minutes 
 
Phase 3: Cool Down              Walk slowly for:                5 minutes 
Month 3:  Phase 1: Warm-up                Walk slowly for:                5 minutes 
 
Phase 2: Brisk Walking       Walk more briskly for:     25-30 minutes 
 
Phase 3: Cool Down              Walk slowly for:                5 minutes          
 
 How Often to Walk? Start with short distances every day and build-up to 3 -5 times per 
week.  
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Figure 4a:  Total Cohort, Survival by Group 
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Figure 4b:  Resected Pancreas Cancer Patients Only, Survival by Group 
 
 
 
